Bluebird tweaks partnership with Lonza to boost Zynteglo, Skysona manufacturing capacity
Bluebird bio is amending its deal with Lonza for the Swiss CDMO to boost the manufacturing capacity of bluebird’s approved gene therapies Zynteglo and Skysona.
The revised deal, agreed upon on Sept. 21, tweaks both companies’ fee scheduling and payment structures, modifies payment terms and updates certain notification and termination provisions, per an SEC filing by bluebird on Wednesday.
Financial details to the changes were not disclosed. Lonza manufactures the two gene therapies at a site in Houston. The partnership was initially locked in June 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.